SEROLOGY RESULTS

SARS-CoV-2 IgG and IgM Panel

Client Accession ID: Viracor Eurofins Accession No: 2004090317
Collected: 04/09/2020 13:57
Final - Approved 04/09/2020 15:00
Performed at: Boston Heart Diagnostics, Level 2, 200 Crossing Boulevard, Framingham, MA 01702 CLIA # 22D2100622

<table>
<thead>
<tr>
<th>TEST</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REF RANGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>SARS-CoV-2 IgG</td>
<td>5.67</td>
<td>H</td>
<td>AU/mL</td>
<td>&lt;1.00</td>
</tr>
</tbody>
</table>

A result greater than or equal to 1.00 AU/mL is considered to be positive. A result less than 1.00 AU/mL is considered to be negative. Negative results do not rule out SARS-CoV-2 exposure. For samples with concentrations near the cut-off or positive, follow-up tests should be performed. Positive IgG antibody results are often present late in the infectious process. (from 7 days onward). This test does not have cross reactivity to non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E. It also does not have cross reactivity to other common viruses including influenza A and B. Results will be reported to government agencies as required.

This test was developed and its performance characteristics determined by Boston Heart Diagnostics. It has not been reviewed, cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Results should be used in conjunction with clinical findings, and should not form the sole basis for a diagnosis or treatment decision. Methods: SARS-CoV-2 IgG: Chemiluminescent Immunoassay.

SARS-CoV-2 IgM | 3.54 | H | AU/mL | <1.00 |

A result greater than or equal to 1.00 AU/mL is considered to be positive. A result less than 1.00 AU/mL is considered to be negative. Negative results do not rule out SARS-CoV-2 exposure. For samples with concentrations near the cut-off or positive, follow-up tests should be performed. Positive IgM antibody results are often present early in the infectious process. This test does not have cross reactivity to non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E. It also does not have cross reactivity to other common viruses including influenza A and B. Results will be reported to government agencies as required.

This test was developed and its performance characteristics determined by Boston Heart Diagnostics. It has not been reviewed, cleared or approved by the U.S. Food and Drug Administration (FDA). The FDA has determined that such clearance is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research. Results should be used in conjunction with clinical findings, and should not form the sole basis for a diagnosis or treatment decision. Methods: SARS-CoV-2 IgM: Chemiluminescent Immunoassay.